MAG: Myelin-associated glycoprotein
Adhesion molecule that mediates interactions between myelinating cells and neurons by binding to neuronal sialic acid- containing gangliosides and to the glycoproteins RTN4R and RTN4RL2.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on MAG, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Refanezumab | Phase 2 | GSK | Antibody | InhibitorMyelin-associated glycoprotein inhibitor | 0 |
- Autosomal recessive spastic paraplegia type 750.79
- Complex hereditary spastic paraplegia0.37
- Orofacial cleft 10.27
- Hereditary disease0.19
- Hereditary spastic paraplegia0.17
- Neuropathy0.11
- Chronic inflammatory demyelinating polyradiculoneuropathy0.11
- Parkinson disease0.10
- Guillain-Barre syndrome, familial0.10
- Stroke disorder0.10
- Monoclonal gammopathy0.09
- Diabetes mellitus0.09
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5807, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P20916, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets